Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 10/20 | 0.62 |
| ▸ | FUCA1 | P04066 | 4/20 | 0.38 |
| ▸ | GLA | P06280 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GLB1 | P16278 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6857528 | 1.00 | GBA1 (0.62) | GBA1FUCA1GLAGAAGLB1 | |
| SCHEMBL17082827 | 1.00 | GBA1 (0.62) | GBA1FUCA1GLAGAAGLB1 | |
| SCHEMBL17082822 | 0.84 | GBA1 (0.71) | GBA1FUCA1GLAGAAGLB1 | |
| SCHEMBL18216800 | 0.84 | GBA1 (0.53) | GBA1FUCA1GLAGAAGLB1 | |
| SCHEMBL6856926 | 0.84 | GBA1 (0.71) | GBA1FUCA1GLAGAAGLB1 | |
| SCHEMBL6857530 | 0.84 | GBA1 (0.53) | GBA1FUCA1GLAGAAGLB1 | |
| SCHEMBL17082832 | 0.84 | GBA1 (0.53) | GBA1FUCA1GLAGAAGLB1 | |
| SCHEMBL17082826 | 0.83 | GBA1 (0.54) | GBA1FUCA1GLAGAAGLB1 | |
| SCHEMBL17082840 | 0.80 | GBA1 (0.45) | GBA1FUCA1GLAGAAGLB1 | |
| SCHEMBL18255197 | 0.80 | GBA1 (0.45) | GBA1FUCA1GLAGAAGLB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160326114-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS, INC. (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326114-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS, INC. (US) | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326114-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | GAP43, CHAT, PMP22 | GBA1 337/4885FUCA1 626/4885GLA 1323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.